In frontline settings, the use of Flt3 inhibitors in combination with chemotherapy or Ven/HMA, CPX351 in therapy-related and MR AML, and IDH inhibitors with azacitidine has altered our viewpoints and practical methods. Here, IDH1 is linked to acute myeloid leukemia.